1. Home
  2. AACB vs SLP Comparison

AACB vs SLP Comparison

Compare AACB & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AACB
  • SLP
  • Stock Information
  • Founded
  • AACB 2024
  • SLP 1996
  • Country
  • AACB United States
  • SLP United States
  • Employees
  • AACB N/A
  • SLP N/A
  • Industry
  • AACB
  • SLP EDP Services
  • Sector
  • AACB
  • SLP Technology
  • Exchange
  • AACB Nasdaq
  • SLP Nasdaq
  • Market Cap
  • AACB 283.7M
  • SLP 322.4M
  • IPO Year
  • AACB 2025
  • SLP 1997
  • Fundamental
  • Price
  • AACB $10.27
  • SLP $17.60
  • Analyst Decision
  • AACB
  • SLP Buy
  • Analyst Count
  • AACB 0
  • SLP 8
  • Target Price
  • AACB N/A
  • SLP $26.80
  • AVG Volume (30 Days)
  • AACB 4.2K
  • SLP 432.7K
  • Earning Date
  • AACB 01-01-0001
  • SLP 12-01-2025
  • Dividend Yield
  • AACB N/A
  • SLP N/A
  • EPS Growth
  • AACB N/A
  • SLP N/A
  • EPS
  • AACB N/A
  • SLP N/A
  • Revenue
  • AACB N/A
  • SLP $80,383,000.00
  • Revenue This Year
  • AACB N/A
  • SLP $13.67
  • Revenue Next Year
  • AACB N/A
  • SLP $1.50
  • P/E Ratio
  • AACB N/A
  • SLP N/A
  • Revenue Growth
  • AACB N/A
  • SLP 20.01
  • 52 Week Low
  • AACB $9.85
  • SLP $12.39
  • 52 Week High
  • AACB $10.27
  • SLP $37.67
  • Technical
  • Relative Strength Index (RSI)
  • AACB N/A
  • SLP 57.31
  • Support Level
  • AACB N/A
  • SLP $16.55
  • Resistance Level
  • AACB N/A
  • SLP $17.83
  • Average True Range (ATR)
  • AACB 0.00
  • SLP 0.84
  • MACD
  • AACB 0.00
  • SLP -0.06
  • Stochastic Oscillator
  • AACB 0.00
  • SLP 44.65

About AACB Artius II Acquisition Inc. Class A Ordinary Shares

Artius II Acquisition Inc is a blank check company.

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Share on Social Networks: